Age: 41.0
Sex: F
Vaccine: COVID19, FLUX
Symptoms: Body temperature, Dyspnoea, Immunisation, Product use issue, Pyrexia
Clinical narrative: Shortness of breath; high fever (103.8); redness and swelling of injection site; redness and swelling of injection site; Booster dose; Dose number 3: 12Dec2021/Flu vaccine: 12Dec2021; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 12Dec2021 11:00 (Lot number: 3303080) at the age of 41 years as dose 3 (booster), single for covid-19 immunisation; influenza vaccine (INFLUENZA VACCINE), administered in arm right, administration date 12Dec2021 (Batch/Lot number: unknown) as unk unk, single. Relevant medical history included: "High blood pressure" (unspecified if ongoing); "ADHD" (unspecified if ongoing); "Allergies: Tomatoes" (unspecified if ongoing), notes: environmental (trees,grass mold, dust, ect.); "Allergies: environmental" (unspecified if ongoing), notes: environmental (trees,grass mold, dust, ect.); "Allergies: trees" (unspecified if ongoing), notes: environmental (trees,grass mold, dust, ect.); "Allergies: mold" (unspecified if ongoing), notes: environmental (trees,grass mold, dust, ect.); "Allergies: Grass" (unspecified if ongoing), notes: environmental (trees,grass mold, dust, ect.); "Allergies: Dust" (unspecified if ongoing), notes: environmental (trees,grass mold, dust, ect.). Concomitant medication(s) included: ADDERALL; CLARITIN ALLERGIC; CITIRIZINE [CETIRIZINE HYDROCHLORIDE]. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: Ep7533, Location of injection: Arm Right, Vaccine Administration Time: 10:45 AM), administration date: 21Apr2021, when the patient was 40 years old, for Covid-19 Immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: Er2613, Location of injection: Arm Right, Vaccine Administration Time: 10:45 AM), administration date: 31Mar2021, when the patient was 40 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 12Dec2021 11:00, outcome "unknown", described as "Booster dose"; PRODUCT USE ISSUE (non-serious) with onset 12Dec2021, outcome "unknown", described as "Dose number 3: 12Dec2021/Flu vaccine: 12Dec2021"; DYSPNOEA (non-serious) with onset 12Dec2021 19:00, outcome "recovered" (16Dec2021), described as "Shortness of breath"; PYREXIA (non-serious) with onset 12Dec2021 19:00, outcome "recovered" (16Dec2021), described as "high fever (103.8)"; VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE SWELLING (non-serious) all with onset 12Dec2021 19:00, outcome "not recovered" and all described as "redness and swelling of injection site". The events "shortness of breath", "high fever (103.8)", "redness and swelling of injection site" and "redness and swelling of injection site" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of dyspnoea, pyrexia, vaccination site erythema, vaccination site swelling.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was nor diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. Device date was on 15Dec2021. As a treatment for adverse events the patient was received Prednisone, albuterol inhaler, epipen.